ロード中...
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Recently, a firmer understanding of tumor immunology and tumor escape mechanisms has led to the development of immune checkpoint inhibitors, antibodies against programmed death-1 (PD-1) and its ligand (PD-L1). Nivolumab, pembrolizumab, and atezolizumab have dramatically altered the treatment paradig...
保存先:
| 出版年: | Ann Transl Med |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635257/ https://ncbi.nlm.nih.gov/pubmed/29057236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2017.06.48 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|